Who makes Salmeterol/Fluticasone Capsair®?

Salmeterol/Fluticasone Capsair® is developed by Neutec Ar-Ge San ve Tic A.Ş.

What development phase is Salmeterol/Fluticasone Capsair® in?

Salmeterol/Fluticasone Capsair® is FDA-approved (marketed).

What are the side effects of Salmeterol/Fluticasone Capsair®?

Common side effects include Tremor, Headache, Palpitations, Oral candidiasis, Hoarseness, Nervousness/anxiety.

Last reviewed 2026-04-22 · How we verify

Salmeterol/Fluticasone Capsair®

Neutec Ar-Ge San ve Tic A.Ş · FDA-approved active Small molecule

Salmeterol/Fluticasone is a combination inhaled bronchodilator and corticosteroid that relaxes airway smooth muscle and reduces airway inflammation.

Salmeterol/Fluticasone is a combination inhaled bronchodilator and corticosteroid that relaxes airway smooth muscle and reduces airway inflammation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic name	Salmeterol/Fluticasone Capsair®
Also known as	Serair 50/500 mcg Capsair® Inhalation Powder
Sponsor	Neutec Ar-Ge San ve Tic A.Ş
Drug class	Long-acting beta-2 agonist/inhaled corticosteroid combination (LABA/ICS)
Target	Beta-2 adrenergic receptor; glucocorticoid receptor
Modality	Small molecule
Therapeutic area	Respiratory/Pulmonology
Phase	FDA-approved

Mechanism of action

Salmeterol is a long-acting beta-2 adrenergic agonist (LABA) that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow. Fluticasone is an inhaled corticosteroid that suppresses airway inflammation by binding to glucocorticoid receptors, reducing mucus production and airway edema. Together, they provide both acute bronchodilation and chronic anti-inflammatory effects for sustained asthma and COPD control.

Approved indications

Asthma maintenance therapy
Chronic obstructive pulmonary disease (COPD) maintenance therapy

Common side effects

Tremor
Headache
Palpitations
Oral candidiasis
Hoarseness
Nervousness/anxiety

Key clinical trials

Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Salmeterol/Fluticasone Capsair® CI brief — competitive landscape report
Salmeterol/Fluticasone Capsair® updates RSS · CI watch RSS
Neutec Ar-Ge San ve Tic A.Ş portfolio CI